This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Lung Cancer
+1

Increasing Adherence to Lung Cancer Screening

Sponsored by Abramson Cancer Center at Penn Medicine

About this trial

Last updated 2 years ago

Study ID

UPCC 09522

Status

Recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
50 to 80 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 7 months ago

What is this trial about?

Investigators are conducting a pragmatic randomized trial testing the effectiveness of patient and clinician nudge strategies on adherence to lung cancer screening (LCS) & diagnostic follow-up across eligible primary care clinicians & patients. Following the trial, a subsample of patients & clinicians will be invited to one-time semi-structured interview & survey to identify individual & system-level factors that may restrict or enhance the impact of strategies.

What are the participation requirements?

Yes

Inclusion Criteria

Clinicians will be eligible if they: 1. are practicing primary care or specialty care physicians at a recruiting site within the University of Pennsylvania Health System; 2. care for patients who completed LCS via LDCT in 2019-2023; and 3. do not opt-out of study participation. Patients will be eligible if they: 1. are eligible for LCS based on 2021 US Preventive Services Task Force (USPSTF) population guidelines (aged 50-80; smoking history of 20-pack years; smoked within the last 15 years) 2. completed LCS via LDCT in 2019-2023; 3. have not been diagnosed with lung cancer; 4. meet criteria for non-adherence; 5. remain eligible for LCS during the trial enrollment period; and 6. receive LCS care from a clinician that has not opted-out of study participation

No

Exclusion Criteria

Patients will be excluded if they: a) have a highly suspicious baseline LDCT (Lung-RADS 4B/X) given the presence of existing clinical pathways to ensure adherence in this group

Locations

Location

Status

Recruiting